Literature DB >> 9035103

Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo.

G J Lieschke1, P K Rao, M K Gately, R C Mulligan.   

Abstract

Interleukin-12 (IL-12) is unique amongst cytokines in being a disulfide-linked heterodimer of two separately encoded subunits (p35 and p40). We expressed single chain IL-12 proteins from retroviral constructs in which the two IL-12 subunits were linked by a 6-15 amino acid polypeptide linker, with deletion of the 22 amino acid leader sequence of the trailing subunit. The murine fusion protein IL-12.p40.L.delta p35 containing a (Gly4Ser)3 linker was stably expressed, bioactive in vitro, and had an apparent specific activity comparable to that of native and recombinant IL-12. Western blotting confirmed that murine IL-12.p40.L.delta p35 retained the linking polypeptide sequences. The analogous human IL-12.p40.L.delta p35 fusion protein containing a Gly6Ser linker was bioactive with an apparent specific activity comparable to recombinant human IL-12. In a preexisting CMS-5 tumor model, CMS-5 cells secreting either native or fusion protein forms of IL-12 prolonged survival and led to complete tumor regression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9035103     DOI: 10.1038/nbt0197-35

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  35 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

Authors:  Sid P Kerkar; Pawel Muranski; Andrew Kaiser; Andrea Boni; Luis Sanchez-Perez; Zhiya Yu; Douglas C Palmer; Robert N Reger; Zachary A Borman; Ling Zhang; Richard A Morgan; Luca Gattinoni; Steven A Rosenberg; Giorgio Trinchieri; Nicholas P Restifo
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

3.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

Review 4.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

5.  Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.

Authors:  J Poutou; M Bunuales; M Gonzalez-Aparicio; E Garcia-Aragoncillo; J I Quetglas; R Casado; C Bravo-Perez; P Alzuguren; R Hernandez-Alcoceba
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

6.  DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.

Authors:  Mariana Manrique; Ewa Micewicz; Pamela A Kozlowski; Shainn-Wei Wang; Deepti Aurora; Robert L Wilson; Musie Ghebremichael; Gail Mazzara; David Montefiori; Angela Carville; Keith G Mansfield; Anna Aldovini
Journal:  AIDS Res Hum Retroviruses       Date:  2008-03       Impact factor: 2.205

7.  Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.

Authors:  Rūta Veinalde; Christian Grossardt; Laura Hartmann; Marie-Claude Bourgeois-Daigneault; John C Bell; Dirk Jäger; Christof von Kalle; Guy Ungerechts; Christine E Engeland
Journal:  Oncoimmunology       Date:  2017-01-31       Impact factor: 8.110

8.  DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Authors:  Sachin Gupta; Emily S Clark; James M Termini; Justin Boucher; Saravana Kanagavelu; Celia C LeBranche; Sakhi Abraham; David C Montefiori; Wasif N Khan; Geoffrey W Stone
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

9.  Optimizing the stability of single-chain proteins by linker length and composition mutagenesis.

Authors:  C R Robinson; R T Sauer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

10.  Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma.

Authors:  H N Lode; T Dreier; R Xiang; N M Varki; A S Kang; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.